SLC27A1

Summary

SLC27A1 (solute carrier family 27 member 1, HGNC:10995) is a protein-coding gene on chromosome 19p13.11, encoding Long-chain fatty acid transport protein 1 (Q6PCB7). Mediates the import of long-chain fatty acids (LCFA) into the cell by facilitating their transport at the plasma membrane.

Enables biotin transmembrane transporter activity; efflux transmembrane transporter activity; and long-chain fatty acid transmembrane transporter activity. Involved in export across plasma membrane; lipid transport across blood-brain barrier; and monocarboxylic acid transport. Located in plasma membrane.

Source: NCBI Gene 376497 — RefSeq curated summary.

At a glance

• GWAS associations: 2
• Clinical variants (ClinVar): 44 total
• Druggable target: yes
• MANE Select transcript: NM_198580

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:10995
Approved symbol	SLC27A1
Name	solute carrier family 27 member 1
Location	19p13.11
Locus type	gene with protein product
Status	Approved
Aliases	FATP1, FATP, MGC71751, FLJ00336, ACSVL5
Ensembl gene	ENSG00000130304
Ensembl biotype	protein_coding
OMIM	600691
Entrez	376497

Gene structure

Transcript identifiers

Ensembl transcripts: 32 — 26 protein_coding, 3 nonsense_mediated_decay, 2 retained_intron, 1 protein_coding_CDS_not_defined

ENST00000252595, ENST00000593701, ENST00000594962, ENST00000598424, ENST00000598848, ENST00000599380, ENST00000599965, ENST00000600277, ENST00000600297, ENST00000865644, ENST00000865645, ENST00000865646, ENST00000865647, ENST00000865648, ENST00000865649, ENST00000865650, ENST00000865651, ENST00000865652, ENST00000865653, ENST00000865654, ENST00000865655, ENST00000865656, ENST00000970235, ENST00000970236, ENST00000970237, ENST00000970238, ENST00000970239, ENST00000970240, ENST00000970241, ENST00000970242, ENST00000970243, ENST00000970244

RefSeq mRNA: 1 — MANE Select: NM_198580 NM_198580

CCDS: CCDS32953

Canonical transcript exons

ENST00000252595 — 12 exons

Exon	Start	End
ENSE00000665599	17487174	17487335
ENSE00001505577	17501273	17501419
ENSE00001703050	17500712	17500876
ENSE00003003279	17470524	17470707
ENSE00003481513	17488848	17488939
ENSE00003546677	17487460	17487529
ENSE00003550557	17486563	17486957
ENSE00003575578	17500495	17500632
ENSE00003619619	17489008	17489117
ENSE00003641665	17497255	17497464
ENSE00003679360	17504455	17506168
ENSE00003682743	17500278	17500404

Expression profiles

Bgee: expression breadth ubiquitous, 233 present calls, max score 93.66.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 8.1646 / max 96.5209, expressed in 1686 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
174521	6.7858	1662
174517	0.5125	168
174516	0.4382	172
174520	0.4282	228

Top tissues by expression

250 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
apex of heart	UBERON:0002098	93.66	gold quality
pancreatic ductal cell	CL:0002079	93.10	silver quality
right hemisphere of cerebellum	UBERON:0014890	92.56	gold quality
cerebellar hemisphere	UBERON:0002245	91.61	gold quality
cerebellar cortex	UBERON:0002129	91.54	gold quality
hindlimb stylopod muscle	UBERON:0004252	91.22	gold quality
left ovary	UBERON:0002119	91.20	gold quality
sural nerve	UBERON:0015488	91.12	gold quality
right ovary	UBERON:0002118	91.11	gold quality
cerebellum	UBERON:0002037	91.01	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	90.60	gold quality
right adrenal gland cortex	UBERON:0035827	90.56	gold quality
left ventricle myocardium	UBERON:0006566	90.52	silver quality
cardiac muscle of right atrium	UBERON:0003379	90.45	silver quality
right adrenal gland	UBERON:0001233	90.20	gold quality
tibialis anterior	UBERON:0001385	90.17	silver quality
spinal cord	UBERON:0002240	90.12	gold quality
heart left ventricle	UBERON:0002084	89.88	gold quality
right uterine tube	UBERON:0001302	89.79	gold quality
peripheral nervous system	UBERON:0000010	89.61	gold quality
tibial nerve	UBERON:0001323	89.61	gold quality
right frontal lobe	UBERON:0002810	89.60	gold quality
cardiac ventricle	UBERON:0002082	89.51	gold quality
left adrenal gland cortex	UBERON:0035825	89.48	gold quality
amygdala	UBERON:0001876	89.46	gold quality
left adrenal gland	UBERON:0001234	89.32	gold quality
adrenal cortex	UBERON:0001235	89.20	gold quality
right atrium auricular region	UBERON:0006631	89.18	gold quality
putamen	UBERON:0001874	89.12	gold quality
cardiac atrium	UBERON:0002081	89.04	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	4.91

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): NR2C2, PPARA, PPARD

miRNA regulators (miRDB)

59 targeting SLC27A1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4455	100.00	65.48	1587
HSA-MIR-19A-3P	99.98	75.33	2762
HSA-MIR-19B-3P	99.98	75.44	2754
HSA-MIR-551B-5P	99.96	71.28	3493
HSA-MIR-145-5P	99.92	71.13	1836
HSA-MIR-5195-3P	99.92	70.92	1877
HSA-MIR-124-3P	99.89	73.74	3043
HSA-MIR-506-3P	99.89	73.55	3057
HSA-MIR-7162-3P	99.89	68.16	1682
HSA-MIR-4496	99.88	68.89	2236
HSA-MIR-1321	99.84	65.30	1811
HSA-MIR-4756-5P	99.84	64.98	1809
HSA-MIR-4739	99.84	65.25	1832
HSA-MIR-548AJ-5P	99.78	71.12	3085
HSA-MIR-548G-5P	99.78	71.12	3085
HSA-MIR-548X-5P	99.78	71.12	3085
HSA-MIR-548F-5P	99.78	71.02	3093
HSA-MIR-6764-5P	99.75	67.89	2304
HSA-MIR-92A-2-5P	99.75	67.01	2164
HSA-MIR-3714	99.71	70.74	2671
HSA-MIR-12124	99.68	69.17	2700
HSA-MIR-519A-3P	99.67	71.67	1868
HSA-MIR-519B-3P	99.67	71.67	1868
HSA-MIR-519C-3P	99.67	71.67	1870
HSA-MIR-1827	99.63	68.57	3265
HSA-MIR-1915-3P	99.58	66.79	1988
HSA-MIR-7106-5P	99.53	67.47	3574
HSA-MIR-4441	99.49	66.56	3216
HSA-MIR-542-3P	99.34	67.58	1270
HSA-MIR-4291	99.20	68.88	2969

Literature-anchored findings (GeneRIF, showing 12)

• exogenously supplied fatty acids are preferentially channeled by an FATP1-linked mechanism into the TG biosynthetic pathway; such internalized lipids downregulate de novo sphingomyelin and cholesterol metabolism in growing 293 cells (PMID:12235169)
• FATP1 might play a role in post-prandial lipid metabolism and development of cardiovascular disease. (PMID:12818409)
• FATP1 stimulated transport and consumption of palmitate and oleate, which they channeled away from complete oxidation and toward TAG synthesis. (PMID:15897321)
• These data reveals the localization and points to a regulatory function of FATP1 in myotube mitochondria. (PMID:19361580)
• FATP1 inhibits 11-cis retinol formation via interaction with the visual cycle retinoid isomerase RPE65 and lecithin:retinol acyltransferase (PMID:20356843)
• Several proteins that are expressed in the epidermis have been proposed to facilitate the uptake of long-chain fatty acids (LCFA) in mammalian cells, CD36, fatty acid binding protein, and FATP. [review] (PMID:24120574)
• Neonatal phthalate ester exposure induced placental MTs, FATP1 and HFABP mRNA expression (PMID:26867681)
• In transgenic mice, lipid droplets accumulation induced by retinal pigment cells (RPCs)-specific expression of human FATP1 was non-toxic and promoted mitochondrial energy metabolism in RPCs and non-autonomously in photoreceptor cells. (PMID:30199545)
• The inhibition of Fatp1 by tumor necrosis factor alpha alleviated oleate-induced total FFA and TG accumulation in macrophages. (PMID:30674874)
• we have established for the first time that FATP1 is a major contributor to docosahexaenoic acid efflux from human brain capillary endothelial cells (PMID:31091338)
• Unraveling FATP1, regulated by ER-beta, as a targeted breast cancer innovative therapy. (PMID:31575907)
• The role of FATP1 in lipid accumulation: a review. (PMID:33486652)

Cross-species orthologs

28 orthologs

Organism	Symbol	Gene ID
danio_rerio	slc27a1a	ENSDARG00000006240
danio_rerio	slc27a1b	ENSDARG00000104949
mus_musculus	Slc27a1	ENSMUSG00000031808
rattus_norvegicus	Slc27a1	ENSRNOG00000018170
drosophila_melanogaster	bgm	FBGN0027348
drosophila_melanogaster	pdgy	FBGN0027601
drosophila_melanogaster	CG8834	FBGN0033733
drosophila_melanogaster	CG17999	FBGN0034552
drosophila_melanogaster	CG9993	FBGN0034553
drosophila_melanogaster	Fatp3	FBGN0034999
drosophila_melanogaster	CG4563	FBGN0035006
drosophila_melanogaster	CG5568	FBGN0035641
drosophila_melanogaster	CG18586	FBGN0035642
drosophila_melanogaster	CG4830	FBGN0037996
drosophila_melanogaster	Acsx1L	FBGN0038730
drosophila_melanogaster	Acsx1R	FBGN0038731
drosophila_melanogaster	Acsx2	FBGN0038732
drosophila_melanogaster	Acsx3	FBGN0038733
drosophila_melanogaster	Acsx4	FBGN0038734
drosophila_melanogaster	Fatp2	FBGN0265187
drosophila_melanogaster	Fatp1	FBGN0267828
drosophila_melanogaster	hll	FBGN0286723
caenorhabditis_elegans		WBGENE00007082
caenorhabditis_elegans		WBGENE00008669
caenorhabditis_elegans		WBGENE00009218
caenorhabditis_elegans		WBGENE00011173
caenorhabditis_elegans		WBGENE00019920
caenorhabditis_elegans		WBGENE00022849

Paralogs (12): ACSL4 (ENSG00000068366), SLC27A5 (ENSG00000083807), ACSBG1 (ENSG00000103740), SLC27A6 (ENSG00000113396), ACSL3 (ENSG00000123983), ACSBG2 (ENSG00000130377), SLC27A2 (ENSG00000140284), SLC27A3 (ENSG00000143554), ACSL1 (ENSG00000151726), ACSL6 (ENSG00000164398), SLC27A4 (ENSG00000167114), ACSL5 (ENSG00000197142)

Protein

Protein identifiers

Long-chain fatty acid transport protein 1 — Q6PCB7 (reviewed: Q6PCB7)

Alternative names: Arachidonate–CoA ligase, Fatty acid transport protein 1, Long-chain-fatty-acid–CoA ligase, Solute carrier family 27 member 1, Very long-chain acyl-CoA synthetase

All UniProt accessions (4): Q6PCB7, B7Z225, M0QXY2, M0QZC9

UniProt curated annotations — full annotation on UniProt →

Function. Mediates the import of long-chain fatty acids (LCFA) into the cell by facilitating their transport at the plasma membrane. Also functions as an acyl-CoA ligase catalyzing the ATP-dependent formation of fatty acyl-CoA using LCFA and very-long-chain fatty acids (VLCFA) as substrates, which prevents fatty acid efflux from cells and might drive more fatty acid uptake. May act directly as a bona fide transporter, or alternatively, in a cytoplasmic or membrane-associated multimeric protein complex to trap and draw fatty acids towards accumulation. Plays a pivotal role in regulating available LCFA substrates from exogenous sources in tissues undergoing high levels of beta-oxidation or triglyceride synthesis. May be involved in regulation of cholesterol metabolism. Probably involved in fatty acid transport across the blood barrier.

Subunit / interactions. Self-associates. May function as a homodimer. Interacts with EPRS1; mediates the translocation of SLC27A1 from the cytoplasm to the plasma membrane thereby increasing the uptake of long-chain fatty acids. Interacts with DGAT2 and this interaction is enhanced in the presence of ZFYVE1.

Subcellular location. Cell membrane. Endomembrane system. Cytoplasm.

Tissue specificity. Highest levels of expression are detected in muscle and adipose tissue small, intermediate levels in small intestine, and barely detectable in liver. Expressed in brain gray matter.

Activity regulation. Inhibited by Triacsin C.

Similarity. Belongs to the ATP-dependent AMP-binding enzyme family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q6PCB7-1	1	yes
Q6PCB7-2	2

RefSeq proteins (1): NP_940982* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000873	AMP-dep_synth/lig_dom	Domain
IPR020845	AMP-binding_CS	Conserved_site
IPR025110	AMP-bd_C	Domain
IPR042099	ANL_N_sf	Homologous_superfamily
IPR045851	AMP-b_sf	Homologous_superfamily

Pfam: PF00501, PF13193

Catalyzed reactions (Rhea), 9 shown:

• a long-chain fatty acid + ATP + CoA = a long-chain fatty acyl-CoA + AMP + diphosphate (RHEA:15421)
• (5Z,8Z,11Z,14Z)-eicosatetraenoate + ATP + CoA = (5Z,8Z,11Z,14Z)-eicosatetraenoyl-CoA + AMP + diphosphate (RHEA:19713)
• tetracosanoate + ATP + CoA = tetracosanoyl-CoA + AMP + diphosphate (RHEA:33639)
• (9Z)-octadecenoate(out) = (9Z)-octadecenoate(in) (RHEA:33655)
• a fatty acid(in) = a fatty acid(out) (RHEA:38879)
• hexadecanoate(out) = hexadecanoate(in) (RHEA:45256)
• (9Z,12Z)-octadecadienoate(out) = (9Z,12Z)-octadecadienoate(in) (RHEA:45264)
• a very long-chain fatty acid + ATP + CoA = a very long-chain fatty acyl-CoA + AMP + diphosphate (RHEA:54536)
• (5Z,8Z,11Z,14Z)-eicosatetraenoate(out) = (5Z,8Z,11Z,14Z)-eicosatetraenoate(in) (RHEA:71395)

UniProt features (8 total): topological domain 2, splice variant 2, chain 1, transmembrane region 1, region of interest 1, binding site 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q6PCB7-F1	91.21	0.70

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (1): 246–257

Function

Pathways and Gene Ontology

Reactome pathways

10 pathways

ID	Pathway
R-HSA-1989781	PPARA activates gene expression
R-HSA-2142753	Arachidonate metabolism
R-HSA-804914	Transport of fatty acids
R-HSA-1430728	Metabolism
R-HSA-382551	Transport of small molecules
R-HSA-400206	Regulation of lipid metabolism by PPARalpha
R-HSA-425397	Transport of vitamins, nucleosides, and related molecules
R-HSA-425407	SLC-mediated transmembrane transport
R-HSA-556833	Metabolism of lipids
R-HSA-8978868	Fatty acid metabolism

MSigDB gene sets: 222 (showing top): GSE45365_CTRL_VS_MCMV_INFECTION_NK_CELL_UP, GOBP_RESPONSE_TO_NITROGEN_COMPOUND, GOBP_CARBOHYDRATE_TRANSPORT, GOBP_RESPONSE_TO_COLD, GOBP_CIRCULATORY_SYSTEM_PROCESS, GOBP_REGULATION_OF_TRIGLYCERIDE_METABOLIC_PROCESS, GOBP_RESPONSE_TO_PEPTIDE, YAO_HOXA10_TARGETS_VIA_PROGESTERONE_UP, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_UP, GRAESSMANN_RESPONSE_TO_MC_AND_DOXORUBICIN_UP, GOBP_REGULATION_OF_HEAT_GENERATION, GOBP_LONG_CHAIN_FATTY_ACID_METABOLIC_PROCESS, GOBP_MONOCARBOXYLIC_ACID_METABOLIC_PROCESS, GOBP_CELLULAR_RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND, GOBP_CELLULAR_RESPONSE_TO_INSULIN_STIMULUS

GO Biological Process (20): medium-chain fatty acid transport (GO:0001579), long-chain fatty acid metabolic process (GO:0001676), response to cold (GO:0009409), positive regulation of triglyceride biosynthetic process (GO:0010867), biotin transport (GO:0015878), long-chain fatty acid transport (GO:0015909), long-chain fatty acid import across plasma membrane (GO:0015911), positive regulation of heat generation (GO:0031652), adiponectin-activated signaling pathway (GO:0033211), glucose import in response to insulin stimulus (GO:0044381), long-chain fatty acid import into cell (GO:0044539), export across plasma membrane (GO:0140115), transport across blood-brain barrier (GO:0150104), biotin import across plasma membrane (GO:1905135), lipid transport across blood-brain barrier (GO:1990379), lipid metabolic process (GO:0006629), fatty acid metabolic process (GO:0006631), lipid transport (GO:0006869), fatty acid transport (GO:0015908), response to insulin (GO:0032868)

GO Molecular Function (13): nucleotide binding (GO:0000166), long-chain fatty acid-CoA ligase activity (GO:0004467), long-chain fatty acid transmembrane transporter activity (GO:0005324), biotin transmembrane transporter activity (GO:0015225), fatty acid transmembrane transporter activity (GO:0015245), efflux transmembrane transporter activity (GO:0015562), very long-chain fatty acid-CoA ligase activity (GO:0031957), identical protein binding (GO:0042802), protein serine/threonine kinase activator activity (GO:0043539), arachidonate-CoA ligase activity (GO:0047676), oleoyl-CoA ligase activity (GO:0090434), protein binding (GO:0005515), ligase activity (GO:0016874)

GO Cellular Component (7): endoplasmic reticulum (GO:0005783), endoplasmic reticulum membrane (GO:0005789), plasma membrane (GO:0005886), basal plasma membrane (GO:0009925), membrane (GO:0016020), cytoplasm (GO:0005737), endomembrane system (GO:0012505)

Reactome top-level categories

Rollup of top-7 pathways:

Category	Pathways
Metabolism of lipids	2
Regulation of lipid metabolism by PPARalpha	1
Fatty acid metabolism	1
Transport of vitamins, nucleosides, and related molecules	1
SLC-mediated transmembrane transport	1
Transport of small molecules	1
Metabolism	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
fatty acid transport	3
cellular anatomical structure	3
monocarboxylic acid transport	2
import across plasma membrane	2
long-chain fatty acid transport	2
biotin transport	2
lipid transport	2
fatty acid-CoA ligase activity	2
monocarboxylic acid transmembrane transporter activity	2
long-chain fatty acid-CoA ligase activity	2
fatty acid metabolic process	1
response to stress	1
response to temperature stimulus	1
regulation of triglyceride biosynthetic process	1
triglyceride biosynthetic process	1
positive regulation of lipid biosynthetic process	1
positive regulation of triglyceride metabolic process	1
vitamin transport	1
nitrogen compound transport	1
sulfur compound transport	1
long-chain fatty acid import into cell	1
fatty acid transmembrane transport	1
heat generation	1
regulation of heat generation	1
positive regulation of multicellular organismal process	1
hormone-mediated signaling pathway	1
cytokine-mediated signaling pathway	1
cellular response to insulin stimulus	1
D-glucose import across plasma membrane	1
import into cell	1
lipid import into cell	1
transmembrane transport	1
export from cell	1
vascular transport	1
vitamin transmembrane transport	1
carboxylic acid transmembrane transport	1
transport across blood-brain barrier	1
primary metabolic process	1
lipid metabolic process	1
monocarboxylic acid metabolic process	1

Protein interactions and networks

STRING

2897 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SLC27A1	DGAT2	Q96PD7	979
SLC27A1	AASDH	Q4L235	931
SLC27A1	SCARB1	Q8WTV0	870
SLC27A1	AWAT1	Q58HT5	843
SLC27A1	CD36	P16671	835
SLC27A1	SCARB2	Q14108	813
SLC27A1	ACSL1	P33121	806
SLC27A1	LIPE	Q05469	749
SLC27A1	ACOX1	Q15067	725
SLC27A1	ACSL5	Q9ULC5	725
SLC27A1	COASY	Q13057	708
SLC27A1	GOT2	P00505	662
SLC27A1	SREBF1	P36956	651
SLC27A1	PLIN1	O60240	650
SLC27A1	FASN	P49327	643

IntAct

38 interactions, top by confidence:

A	B	Type	Score
TRDN	TMEM223	psi-mi:“MI:0914”(association)	0.640
SLC39A4	TMEM120B	psi-mi:“MI:0914”(association)	0.530
EVA1C	STK25	psi-mi:“MI:0914”(association)	0.530
PBXIP1	KCNN4	psi-mi:“MI:0914”(association)	0.530
LDLRAD1	ADAM10	psi-mi:“MI:0914”(association)	0.530
	HAX1	psi-mi:“MI:0914”(association)	0.350
MAPT	SHTN1	psi-mi:“MI:0914”(association)	0.350
FFAR1	SLC12A8	psi-mi:“MI:0914”(association)	0.350
GPR182	SLC12A8	psi-mi:“MI:0914”(association)	0.350
CHRNA1	ESYT2	psi-mi:“MI:0914”(association)	0.350
TSPAN15	TMEM223	psi-mi:“MI:0914”(association)	0.350
PIGH	ILVBL	psi-mi:“MI:0914”(association)	0.350
TTMP	NBAS	psi-mi:“MI:0914”(association)	0.350
SLC22A9	TMEM131L	psi-mi:“MI:0914”(association)	0.350
CD79A	TMEM131L	psi-mi:“MI:0914”(association)	0.350
LDLRAD1	ZNF316	psi-mi:“MI:0914”(association)	0.350
LGR4		psi-mi:“MI:0914”(association)	0.350
ITM2C		psi-mi:“MI:0914”(association)	0.350
SYP	HAS3	psi-mi:“MI:0914”(association)	0.350
CA6	QSOX1	psi-mi:“MI:0914”(association)	0.350
ZDHHC12	FAAH	psi-mi:“MI:0914”(association)	0.350
LPAR2	EI24	psi-mi:“MI:0914”(association)	0.350
PEX19	KCNN4	psi-mi:“MI:0914”(association)	0.350
C1orf210	SPAG9	psi-mi:“MI:0914”(association)	0.350
FSD2	MYO9A	psi-mi:“MI:0914”(association)	0.350
PBXIP1	CEBPZOS	psi-mi:“MI:0914”(association)	0.350
SAAL1	TMEM223	psi-mi:“MI:0914”(association)	0.350
SLC39A12	GPR39	psi-mi:“MI:0914”(association)	0.350

BioGRID (163): SLC27A1 (Affinity Capture-MS), SLC27A1 (Affinity Capture-RNA), SLC27A1 (Affinity Capture-MS), SLC27A1 (Affinity Capture-Western), SLC27A1 (Affinity Capture-MS), SLC27A1 (Affinity Capture-MS), SLC27A1 (Affinity Capture-MS), SLC27A1 (Affinity Capture-MS), SLC27A1 (Affinity Capture-MS), SLC27A1 (Affinity Capture-MS), SLC27A1 (Affinity Capture-MS), SLC27A1 (Affinity Capture-MS), SLC27A1 (Affinity Capture-MS), SLC27A1 (Affinity Capture-MS), SLC27A1 (Affinity Capture-MS)

ESM2 similar proteins: A0A6N3IN21, A3KCL7, A4IFH5, A7MBC0, A7MBI7, D3ZDK7, D3ZDM7, E1BNQ4, P09367, P10950, P11172, P13439, P17256, P20132, P24298, P25409, P31754, P46597, P50053, P97328, Q02974, Q03426, Q0VCW4, Q1JPD3, Q3B8E3, Q3TY86, Q3ZKN0, Q5BJJ5, Q5E9T8, Q5M7T9, Q5R514, Q5R824, Q5RD71, Q5RFE6, Q6PCB7, Q6SKR2, Q80W22, Q8CHP8, Q8CIM3, Q8HZJ0

Diamond homologs: A4TS06, A5JTM6, A6UED8, A6WXV8, A7FNG1, A8G8G7, B2HHZ8, B5ZV36, C3MAS0, E9Q9W4, M4IRL9, O35488, O53551, O95573, P97524, P97849, Q07VK4, Q0S4D7, Q0VSR6, Q1C0N0, Q1CE37, Q21LV0, Q3ZKN0, Q4LDG0, Q5R668, Q60714, Q66FM8, Q6FLU2, Q6PCB7, Q7MGU3, Q7TWC5, Q8D1G8, Q8DCZ9, Q8Z1R0, Q8ZKF6, Q92KX2, Q9CMW1, Q9Y2P5, O05307, O14975

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
SLC27A1	“up-regulates quantity”	“Fatty acid”	relocalization

Disease & clinical

Clinical variants and AI predictions

ClinVar

44 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	33
Likely benign	1
Benign	3

Top pathogenic / likely-pathogenic (0)

SpliceAI

2144 predictions. Top by Δscore:

Variant	Effect	Δscore
19:17470703:CTCTT:C	donor_gain	1.0000
19:17470704:TCTT:T	donor_gain	1.0000
19:17470705:CTT:C	donor_gain	1.0000
19:17470706:TT:T	donor_gain	1.0000
19:17470707:TG:T	donor_loss	1.0000
19:17470708:G:GG	donor_gain	1.0000
19:17470708:GT:G	donor_loss	1.0000
19:17470709:T:G	donor_loss	1.0000
19:17486561:A:AG	acceptor_gain	1.0000
19:17486561:AGC:A	acceptor_gain	1.0000
19:17486561:AGCG:A	acceptor_gain	1.0000
19:17486562:G:GC	acceptor_gain	1.0000
19:17486562:GC:G	acceptor_gain	1.0000
19:17486562:GCG:G	acceptor_gain	1.0000
19:17486562:GCGG:G	acceptor_gain	1.0000
19:17486562:GCGGT:G	acceptor_gain	1.0000
19:17487172:AGC:A	acceptor_gain	1.0000
19:17487173:GCG:G	acceptor_gain	1.0000
19:17487459:GATC:G	acceptor_gain	1.0000
19:17487526:GCAG:G	donor_gain	1.0000
19:17487527:CAGGT:C	donor_loss	1.0000
19:17487529:GGTGA:G	donor_loss	1.0000
19:17487530:GTG:G	donor_loss	1.0000
19:17487531:T:A	donor_loss	1.0000
19:17489105:G:GG	donor_gain	1.0000
19:17497410:G:GT	donor_gain	1.0000
19:17497410:G:T	donor_gain	1.0000
19:17497456:G:GT	donor_gain	1.0000
19:17497476:C:T	donor_gain	1.0000
19:17497507:G:GT	donor_gain	1.0000

AlphaMissense

4154 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
19:17487486:G:T	G251W	0.999
19:17487511:C:A	A259D	0.999
19:17489114:C:G	C331W	0.999
19:17497352:G:A	G365E	0.999
19:17497427:C:T	T390I	0.999
19:17500548:T:C	F463L	0.999
19:17500550:C:A	F463L	0.999
19:17500550:C:G	F463L	0.999
19:17500796:T:A	V519D	0.999
19:17487487:G:A	G251E	0.998
19:17487529:G:T	R265M	0.998
19:17488930:C:G	H293D	0.998
19:17488932:C:A	H293Q	0.998
19:17488932:C:G	H293Q	0.998
19:17489008:G:A	G296E	0.998
19:17489088:T:A	W323R	0.998
19:17489088:T:C	W323R	0.998
19:17497271:G:A	G338E	0.998
19:17497346:G:A	G363E	0.998
19:17497429:G:A	E391K	0.998
19:17497430:A:T	E391V	0.998
19:17500291:G:A	G407D	0.998
19:17500293:T:C	F408L	0.998
19:17500295:C:A	F408L	0.998
19:17500295:C:G	F408L	0.998
19:17500557:T:C	Y466H	0.998
19:17500714:G:C	D492H	0.998
19:17500715:A:C	D492A	0.998
19:17500715:A:G	D492G	0.998
19:17500715:A:T	D492V	0.998

dbSNP variants (sampled 300 via entrez): RS1000123502 (19:17506308 G>C), RS1000266265 (19:17506629 G>A), RS1000314908 (19:17491637 C>T), RS1000319804 (19:17472127 G>A,C), RS1000397305 (19:17472289 G>A), RS1000399964 (19:17483393 T>C), RS1000418840 (19:17485774 G>A), RS1000511125 (19:17476664 A>G), RS1000595469 (19:17489876 C>G,T), RS1000665719 (19:17491327 C>T), RS1000788197 (19:17482404 C>T), RS1000857126 (19:17495695 A>C), RS1000998134 (19:17501374 G>A,T), RS1001130491 (19:17482245 G>A,T), RS1001145374 (19:17478209 G>A)

Disease associations

OMIM: gene MIM:600691 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST000643_6	Response to antidepressants	3.000000e-06
GCST010397_9	Gut microbiota (bacterial taxa, rank normal transformation method)	1.000000e-06

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0007874	gut microbiome measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL2052038 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: transporter — SLC27 family of fatty acid transporters

Most potent curated ligand interactions (1 total), top 1:

Ligand	Action	Affinity	Parameter
compound 5k [PMID: 23528296]	Inhibition	7.34	pIC50

ChEMBL bioactivities

40 potent at pChembl≥5 of 40 total, top 38 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
7.58	IC50	26	nM	CHEMBL2377769
7.39	IC50	41	nM	CHEMBL2377620
7.34	IC50	46	nM	CHEMBL2377621
7.11	IC50	77	nM	CHEMBL2377766
7.00	IC50	100	nM	CHEMBL2058359
7.00	IC50	100	nM	CHEMBL2377611
7.00	IC50	100	nM	CHEMBL2377622
6.92	IC50	120	nM	CHEMBL2377763
6.89	IC50	130	nM	CHEMBL2377617
6.75	IC50	180	nM	CHEMBL2377764
6.72	IC50	190	nM	CHEMBL2058343
6.72	IC50	190	nM	CHEMBL2377610
6.70	IC50	200	nM	CHEMBL2377757
6.64	IC50	230	nM	CHEMBL2058092
6.60	IC50	250	nM	CHEMBL2377761
6.58	IC50	260	nM	CHEMBL2058349
6.55	IC50	280	nM	CHEMBL2377760
6.48	IC50	330	nM	CHEMBL2058076
6.48	IC50	330	nM	CHEMBL2377614
6.44	IC50	360	nM	CHEMBL2058358
6.40	IC50	400	nM	CHEMBL2058339
6.40	IC50	400	nM	CHEMBL2058091
6.37	IC50	430	nM	CHEMBL2377619
6.37	IC50	430	nM	CHEMBL2377767
6.33	IC50	470	nM	CHEMBL2377612
6.31	IC50	490	nM	CHEMBL2377762
6.31	IC50	490	nM	CHEMBL2377765
6.28	IC50	520	nM	CHEMBL2377623
6.27	IC50	540	nM	CHEMBL2058078
6.24	IC50	580	nM	CHEMBL2057220
6.22	IC50	600	nM	CHEMBL2058346
6.17	IC50	680	nM	CHEMBL2058344
6.11	IC50	780	nM	CHEMBL2377618
6.05	IC50	900	nM	CHEMBL2058345
5.78	IC50	1670	nM	CHEMBL2058347
5.52	IC50	3000	nM	CHEMBL2377768
5.18	IC50	6600	nM	CHEMBL2058074
5.12	IC50	7600	nM	CHEMBL2058075

PubChem BioAssay actives

39 with measured affinity, of 76 total; 38 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
2-[4-(4-fluorophenyl)piperazin-1-yl]-N-(5-methyl-4,5,6,7-tetrahydro-1,3-benzothiazol-2-yl)acetamide	744748: Inhibition of human FLAG-tagged FATP1-mediated [1-14C] oleic acid conversion to [1-14C] oleoyl-CoA after 20 mins by scintillation counting analysis	ic50	0.0260	uM
2-[4-(5-fluoro-2-pyridinyl)piperazin-1-yl]-N-methyl-N-(4,5,6,7-tetrahydro-1,3-benzothiazol-2-yl)acetamide	744748: Inhibition of human FLAG-tagged FATP1-mediated [1-14C] oleic acid conversion to [1-14C] oleoyl-CoA after 20 mins by scintillation counting analysis	ic50	0.0410	uM
2-[4-(5-fluoro-2-pyridinyl)piperazin-1-yl]-N-(4,5,6,7-tetrahydro-1,3-benzothiazol-2-yl)acetamide	744748: Inhibition of human FLAG-tagged FATP1-mediated [1-14C] oleic acid conversion to [1-14C] oleoyl-CoA after 20 mins by scintillation counting analysis	ic50	0.0460	uM
2-[4-(4-fluorophenyl)piperazin-1-yl]-N-(4,5,6,7-tetrahydro-1,3-benzothiazol-2-yl)acetamide	744748: Inhibition of human FLAG-tagged FATP1-mediated [1-14C] oleic acid conversion to [1-14C] oleoyl-CoA after 20 mins by scintillation counting analysis	ic50	0.0770	uM
N-[[4-ethyl-5-[[5-(trifluoromethoxy)-1,3-benzoxazol-2-yl]methylsulfanyl]-1,2,4-triazol-3-yl]methyl]aniline	673535: Inhibition of human recombinant FATP1 acyl-coA synthetase activity using [14C]oleic acid as substrate	ic50	0.1000	uM
2-[4-(5-fluoro-2-pyridinyl)piperazin-1-yl]-N-(4,5,6,7-tetrahydro-1,3-benzoxazol-2-yl)acetamide	744748: Inhibition of human FLAG-tagged FATP1-mediated [1-14C] oleic acid conversion to [1-14C] oleoyl-CoA after 20 mins by scintillation counting analysis	ic50	0.1000	uM
2-[4-(5-fluoro-2-pyridinyl)piperazin-1-yl]-1-(5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-3-yl)ethanone	744748: Inhibition of human FLAG-tagged FATP1-mediated [1-14C] oleic acid conversion to [1-14C] oleoyl-CoA after 20 mins by scintillation counting analysis	ic50	0.1000	uM
2-[4-(4-fluorophenyl)piperazin-1-yl]-N-(5,6,7,8-tetrahydro-4H-cyclohepta[d][1,3]thiazol-2-yl)acetamide	744748: Inhibition of human FLAG-tagged FATP1-mediated [1-14C] oleic acid conversion to [1-14C] oleoyl-CoA after 20 mins by scintillation counting analysis	ic50	0.1200	uM
2-[4-(5-fluoro-2-pyridinyl)piperazin-1-yl]-1-imidazo[1,2-a]pyridin-3-ylethanone	744748: Inhibition of human FLAG-tagged FATP1-mediated [1-14C] oleic acid conversion to [1-14C] oleoyl-CoA after 20 mins by scintillation counting analysis	ic50	0.1300	uM
2-[4-(4-fluorophenyl)piperazin-1-yl]-N-(4,5,6,7-tetrahydro-1,3-benzoxazol-2-yl)acetamide	744748: Inhibition of human FLAG-tagged FATP1-mediated [1-14C] oleic acid conversion to [1-14C] oleoyl-CoA after 20 mins by scintillation counting analysis	ic50	0.1800	uM
1-[2-[[5-(anilinomethyl)-4-ethyl-1,2,4-triazol-3-yl]sulfanylmethyl]-1,3-benzoxazol-5-yl]propan-1-one	673535: Inhibition of human recombinant FATP1 acyl-coA synthetase activity using [14C]oleic acid as substrate	ic50	0.1900	uM
2-[4-(5-fluoro-2-pyridinyl)piperazin-1-yl]-1-(2-methyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-3-yl)ethanone	744748: Inhibition of human FLAG-tagged FATP1-mediated [1-14C] oleic acid conversion to [1-14C] oleoyl-CoA after 20 mins by scintillation counting analysis	ic50	0.1900	uM
2-(4-pyridin-2-ylpiperazin-1-yl)-N-(4,5,6,7-tetrahydro-1,3-benzothiazol-2-yl)acetamide	744748: Inhibition of human FLAG-tagged FATP1-mediated [1-14C] oleic acid conversion to [1-14C] oleoyl-CoA after 20 mins by scintillation counting analysis	ic50	0.2000	uM
2-[[5-(anilinomethyl)-4-ethyl-1,2,4-triazol-3-yl]sulfanyl]-N-(4-butanoylphenyl)acetamide	673535: Inhibition of human recombinant FATP1 acyl-coA synthetase activity using [14C]oleic acid as substrate	ic50	0.2300	uM
2-[4-(4-methylphenyl)piperazin-1-yl]-N-(4,5,6,7-tetrahydro-1,3-benzothiazol-2-yl)acetamide	744748: Inhibition of human FLAG-tagged FATP1-mediated [1-14C] oleic acid conversion to [1-14C] oleoyl-CoA after 20 mins by scintillation counting analysis	ic50	0.2500	uM
(NZ)-N-[1-[2-[[5-(anilinomethyl)-4-ethyl-1,2,4-triazol-3-yl]sulfanylmethyl]-1,3-benzoxazol-5-yl]propylidene]hydroxylamine	673535: Inhibition of human recombinant FATP1 acyl-coA synthetase activity using [14C]oleic acid as substrate	ic50	0.2600	uM
2-(4-phenylpiperazin-1-yl)-N-(4,5,6,7-tetrahydro-1,3-benzothiazol-2-yl)acetamide	744748: Inhibition of human FLAG-tagged FATP1-mediated [1-14C] oleic acid conversion to [1-14C] oleoyl-CoA after 20 mins by scintillation counting analysis	ic50	0.2800	uM
ethyl 4-[[2-[[5-(anilinomethyl)-4-ethyl-1,2,4-triazol-3-yl]sulfanyl]acetyl]amino]benzoate	673535: Inhibition of human recombinant FATP1 acyl-coA synthetase activity using [14C]oleic acid as substrate	ic50	0.3300	uM
2-[4-(5-fluoro-2-pyridinyl)piperazin-1-yl]-1-pyrazolo[1,5-a]pyridin-3-ylethanone	744748: Inhibition of human FLAG-tagged FATP1-mediated [1-14C] oleic acid conversion to [1-14C] oleoyl-CoA after 20 mins by scintillation counting analysis	ic50	0.3300	uM
N-[[4-ethyl-5-[[5-(trifluoromethyl)-1,3-benzoxazol-2-yl]methylsulfanyl]-1,2,4-triazol-3-yl]methyl]aniline	673535: Inhibition of human recombinant FATP1 acyl-coA synthetase activity using [14C]oleic acid as substrate	ic50	0.3600	uM
2-[[5-(anilinomethyl)-4-ethyl-1,2,4-triazol-3-yl]sulfanyl]-N-(6-propanoyl-3-pyridinyl)acetamide	673535: Inhibition of human recombinant FATP1 acyl-coA synthetase activity using [14C]oleic acid as substrate	ic50	0.4000	uM
2-[[5-(anilinomethyl)-4-ethyl-1,2,4-triazol-3-yl]sulfanyl]-N-(4-propanoylphenyl)acetamide	673535: Inhibition of human recombinant FATP1 acyl-coA synthetase activity using [14C]oleic acid as substrate	ic50	0.4000	uM
N-(4,5-dimethyl-1,3-thiazol-2-yl)-2-[4-(4-fluorophenyl)piperazin-1-yl]acetamide	744748: Inhibition of human FLAG-tagged FATP1-mediated [1-14C] oleic acid conversion to [1-14C] oleoyl-CoA after 20 mins by scintillation counting analysis	ic50	0.4300	uM
2-[4-(5-fluoro-2-pyridinyl)piperazin-1-yl]-1-(2-methylimidazo[1,2-a]pyridin-3-yl)ethanone	744748: Inhibition of human FLAG-tagged FATP1-mediated [1-14C] oleic acid conversion to [1-14C] oleoyl-CoA after 20 mins by scintillation counting analysis	ic50	0.4300	uM
1-(1-benzofuran-3-yl)-2-[4-(5-fluoro-2-pyridinyl)piperazin-1-yl]ethanone	744748: Inhibition of human FLAG-tagged FATP1-mediated [1-14C] oleic acid conversion to [1-14C] oleoyl-CoA after 20 mins by scintillation counting analysis	ic50	0.4700	uM
N-(1,3-benzothiazol-2-yl)-2-[4-(4-fluorophenyl)piperazin-1-yl]acetamide	744748: Inhibition of human FLAG-tagged FATP1-mediated [1-14C] oleic acid conversion to [1-14C] oleoyl-CoA after 20 mins by scintillation counting analysis	ic50	0.4900	uM
N-(5,6-dihydro-4H-cyclopenta[d][1,3]thiazol-2-yl)-2-[4-(4-fluorophenyl)piperazin-1-yl]acetamide	744748: Inhibition of human FLAG-tagged FATP1-mediated [1-14C] oleic acid conversion to [1-14C] oleoyl-CoA after 20 mins by scintillation counting analysis	ic50	0.4900	uM
N-(4,5,6,7-tetrahydro-1,3-benzothiazol-2-yl)-2-[4-(1,3-thiazol-2-yl)piperazin-1-yl]acetamide	744748: Inhibition of human FLAG-tagged FATP1-mediated [1-14C] oleic acid conversion to [1-14C] oleoyl-CoA after 20 mins by scintillation counting analysis	ic50	0.5200	uM
methyl 4-[[2-[[5-(anilinomethyl)-4-ethyl-1,2,4-triazol-3-yl]sulfanyl]acetyl]amino]benzoate	673535: Inhibition of human recombinant FATP1 acyl-coA synthetase activity using [14C]oleic acid as substrate	ic50	0.5400	uM
2-[[5-(anilinomethyl)-4-ethyl-1,2,4-triazol-3-yl]sulfanyl]-N-methyl-N-(4-propanoylphenyl)acetamide	673535: Inhibition of human recombinant FATP1 acyl-coA synthetase activity using [14C]oleic acid as substrate	ic50	0.5800	uM
1-[2-[[5-(anilinomethyl)-4-ethyl-1,2,4-triazol-3-yl]sulfanylmethyl]-1,3-benzoxazol-5-yl]-2-methylpropan-1-one	673535: Inhibition of human recombinant FATP1 acyl-coA synthetase activity using [14C]oleic acid as substrate	ic50	0.6000	uM
ethyl 2-[[5-(anilinomethyl)-4-ethyl-1,2,4-triazol-3-yl]sulfanylmethyl]-1,3-benzoxazole-5-carboxylate	673535: Inhibition of human recombinant FATP1 acyl-coA synthetase activity using [14C]oleic acid as substrate	ic50	0.6800	uM
N-ethyl-2-[4-(5-fluoro-2-pyridinyl)piperazin-1-yl]-N-(4,5,6,7-tetrahydro-1,3-benzothiazol-2-yl)acetamide	744748: Inhibition of human FLAG-tagged FATP1-mediated [1-14C] oleic acid conversion to [1-14C] oleoyl-CoA after 20 mins by scintillation counting analysis	ic50	0.7800	uM
1-[2-[[5-(anilinomethyl)-4-ethyl-1,2,4-triazol-3-yl]sulfanylmethyl]-1,3-benzoxazol-6-yl]propan-1-one	673535: Inhibition of human recombinant FATP1 acyl-coA synthetase activity using [14C]oleic acid as substrate	ic50	0.9000	uM
1-[2-[[5-(anilinomethyl)-4-ethyl-1,2,4-triazol-3-yl]sulfonylmethyl]-1,3-benzoxazol-5-yl]propan-1-one	673535: Inhibition of human recombinant FATP1 acyl-coA synthetase activity using [14C]oleic acid as substrate	ic50	1.6700	uM
1-(2-methylimidazo[1,2-a]pyridin-3-yl)-2-(4-phenylpiperazin-1-yl)ethanone	744748: Inhibition of human FLAG-tagged FATP1-mediated [1-14C] oleic acid conversion to [1-14C] oleoyl-CoA after 20 mins by scintillation counting analysis	ic50	3.0000	uM
2-[[5-(anilinomethyl)-4-prop-2-enyl-1,2,4-triazol-3-yl]sulfanyl]-N-(4-methoxyphenyl)acetamide	673535: Inhibition of human recombinant FATP1 acyl-coA synthetase activity using [14C]oleic acid as substrate	ic50	6.6000	uM
ethyl 4-[[2-[[5-(benzylsulfanylmethyl)-4-ethyl-1,2,4-triazol-3-yl]sulfanyl]acetyl]amino]benzoate	673535: Inhibition of human recombinant FATP1 acyl-coA synthetase activity using [14C]oleic acid as substrate	ic50	7.6000	uM

CTD chemical–gene interactions

51 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Rosiglitazone	increases expression, decreases expression	3
Valproic Acid	increases methylation, affects expression, increases expression	3
bisphenol A	increases expression	2
Cisplatin	affects expression, affects cotreatment, increases expression	2
Lead	affects expression, decreases expression	2
Nickel	decreases expression	2
afuresertib	increases expression	1
FR900359	increases phosphorylation	1
fluorotelomer sulfonic acids	increases expression	1
diethyl phthalate	increases abundance, increases expression	1
trichostatin A	affects expression	1
arsenite	increases methylation	1
perfluorooctanoic acid	decreases expression	1
aflatoxin B2	increases methylation	1
sulfluramid	increases expression	1
di-n-butylphosphoric acid	affects expression	1
GW 4064	decreases expression, affects cotreatment	1
GW 7647	affects cotreatment, decreases expression	1
6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime	affects cotreatment, decreases expression	1
3-iodothyronamine	affects uptake	1
abrine	decreases expression	1
bisphenol S	increases expression	1
jinfukang	increases expression, affects cotreatment	1
MT19c compound	decreases expression	1
bisphenol AF	increases expression	1
Temozolomide	increases expression	1
Decitabine	affects expression	1
Zoledronic Acid	increases expression	1
Alitretinoin	increases expression	1
Calcitriol	increases expression, affects cotreatment	1

ChEMBL screening assays

3 unique, capped per target: 2 binding, 1 functional

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL2061593	Binding	Inhibition of human recombinant FATP1 acyl-coA synthetase activity using [14C]oleic acid as substrate	Discovery and optimization of novel fatty acid transport protein 1 (FATP1) inhibitors. — Bioorg Med Chem Lett
CHEMBL5723234	Functional	Affinity Biochemical interaction: (cell-free ACS assay) EUB0002574a SLC27A1	Affinity Biochemical Literature for EUbOPEN Chemogenomic Library

Cellosaurus cell lines

4 cell lines: 4 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_D4KQ	HCT116-SLC27A1-KO-c1	Cancer cell line	Male
CVCL_D4KR	HCT116-SLC27A1-KO-c3	Cancer cell line	Male
CVCL_TM63	HAP1 SLC27A1 (-) 1	Cancer cell line	Male
CVCL_TM64	HAP1 SLC27A1 (-) 2	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.